Biolife Solutions annual operating margin
2010
2011
2012
2013
2014
2017
2018
2019
2020
2021
2022
2023
2024
2025
Biolife Solutions's operating margin was −17.26% for fiscal 2025.
View full Biolife Solutions company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −17.26% | −11.26 pp |
| 2024 | 2024-12-31 | −6.00% | +19.30 pp |
| 2023 | 2023-12-31 | −25.30% | −17.53 pp |
| 2022 | 2022-12-31 | −7.77% | +21.74 pp |
| 2021 | 2021-12-31 | −29.51% | −16.53 pp |
| 2020 | 2020-12-31 | −12.98% | −12.17 pp |
| 2019 | 2019-12-31 | −0.80% | −19.35 pp |
| 2018 | 2018-12-31 | 18.55% | +28.13 pp |
| 2017 | 2017-12-31 | −9.58% | +41.07 pp |
| 2014 | 2014-12-31 | −50.65% | −47.46 pp |
| 2013 | 2013-12-31 | −3.19% | +13.45 pp |
| 2012 | 2012-12-31 | −16.64% | +27.21 pp |
| 2011 | 2011-12-31 | −43.85% | +23.13 pp |
| 2010 | 2010-12-31 | −66.98% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 5.96% | +74.76 pp |
| Q1 2026 | 2026-03-31 | 0.10% | +2.36 pp |
| Q4 2025 | 2025-12-31 | 0.49% | −3.09 pp |
| Q3 2025 | 2025-09-30 | −0.32% | +1.64 pp |
| Q2 2025 | 2025-06-30 | −68.80% | −62.18 pp |
| Q1 2025 | 2025-03-31 | −2.26% | +15.61 pp |
| Q4 2024 | 2024-12-31 | 3.59% | +69.23 pp |
| Q3 2024 | 2024-09-30 | −1.95% | +34.40 pp |
| Q2 2024 | 2024-06-30 | −6.62% | +29.46 pp |
| Q1 2024 | 2024-03-31 | −17.88% | +10.94 pp |
| Q3 2023 | 2023-09-30 | −65.65% | +123.24 pp |
| Q2 2023 | 2023-06-30 | −36.35% | −14.36 pp |
| Q1 2023 | 2023-03-31 | −36.08% | +13.41 pp |
| Q3 2022 | 2022-09-30 | −28.81% | +4.20 pp |
| Q2 2022 | 2022-06-30 | −188.89% | −174.29 pp |
| Q1 2022 | 2022-03-31 | −22.00% | −16.17 pp |
| Q4 2021 | 2021-12-31 | −49.50% | −12.77 pp |
| Q3 2021 | 2021-09-30 | −33.01% | −21.97 pp |
| Q2 2021 | 2021-06-30 | −14.60% | −15.04 pp |
| Q1 2021 | 2021-03-31 | −5.82% | −8.87 pp |
| Q4 2020 | 2020-12-31 | −36.73% | −27.56 pp |
| Q3 2020 | 2020-09-30 | −11.05% | +0.64 pp |
| Q2 2020 | 2020-06-30 | 0.44% | −10.70 pp |
| Q1 2020 | 2020-03-31 | 3.04% | −6.77 pp |
| Q4 2019 | 2019-12-31 | −9.17% | −28.27 pp |
| Q3 2019 | 2019-09-30 | −11.69% | −34.27 pp |
| Q2 2019 | 2019-06-30 | 11.15% | −13.67 pp |
| Q1 2019 | 2019-03-31 | 9.81% | +6.14 pp |
| Q4 2018 | 2018-12-31 | 19.10% | +26.07 pp |
| Q3 2018 | 2018-09-30 | 22.58% | +23.67 pp |
| Q2 2018 | 2018-06-30 | 24.82% | +38.16 pp |
| Q1 2018 | 2018-03-31 | 3.67% | +23.28 pp |
| Q4 2017 | 2017-12-31 | −6.97% | +53.15 pp |
| Q3 2017 | 2017-09-30 | −1.09% | +69.24 pp |
| Q2 2017 | 2017-06-30 | −13.34% | +59.92 pp |
| Q1 2017 | 2017-03-31 | −19.61% | −1.74 pp |
| Q4 2014 | 2014-12-31 | −60.12% | −47.68 pp |
| Q3 2014 | 2014-09-30 | −70.33% | −65.26 pp |
| Q2 2014 | 2014-06-30 | −73.26% | −69.71 pp |
| Q1 2014 | 2014-03-31 | −17.87% | −26.78 pp |
| Q4 2013 | 2013-12-31 | −12.44% | +2.58 pp |
| Q3 2013 | 2013-09-30 | −5.07% | +3.77 pp |
| Q2 2013 | 2013-06-30 | −3.56% | +24.39 pp |
| Q1 2013 | 2013-03-31 | 8.90% | +30.35 pp |
| Q4 2012 | 2012-12-31 | −15.02% | +10.99 pp |
| Q3 2012 | 2012-09-30 | −8.84% | +30.96 pp |
| Q2 2012 | 2012-06-30 | −27.94% | +13.80 pp |
| Q1 2012 | 2012-03-31 | −21.45% | +52.93 pp |
| Q4 2011 | 2011-12-31 | −26.01% | +28.51 pp |
| Q3 2011 | 2011-09-30 | −39.80% | +43.90 pp |
| Q2 2011 | 2011-06-30 | −41.75% | — |
| Q1 2011 | 2011-03-31 | −74.37% | — |
| Q3 2010 | 2010-09-30 | −54.52% | — |
| Q2 2010 | 2010-06-30 | −83.70% | — |
Over the last five reported fiscal years, Biolife Solutions's operating margin decreased from −12.98% to −17.26%, a change of −4.28 percentage points. The latest reported quarter, Q2 2026, shows 5.96%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biolife Solutions filings at SEC.gov ↗